Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-23), the Forward Annual Dividend Yield of Zydus Lifesciences is 0.09%.
As of today (2026-07-23), the Trailing Annual Dividend Yield of Zydus Lifesciences is 0.96%.
BOM:532321's Forward Dividend Yield % is ranked worse than 98.04% of 510
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs BOM:532321: 0.09
During the past 12 months, Zydus Lifesciences's average Dividends Per Share Growth Rate was 266.70% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 63.90% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Zydus Lifesciences was 63.90% per year. The lowest was -29.10% per year. And the median was 14.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Zydus Lifesciences Forward Dividend Yield % Related Terms
BOM:532321 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zydus Lifesciences Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Zydus Lifesciences's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Zydus Lifesciences Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 11.000000
2025-07-25
2025-07-25
2025-08-14
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Zydus Lifesciences's Forward Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 0.09% mean?
Zydus Lifesciences (BOM:532321) has a Forward Dividend Yield % of 0.09% as of Jul. 23, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Zydus Lifesciences and its competitors. According to the industry distribution chart, Zydus Lifesciences ranks #500 out of 510 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is Zydus Lifesciences' Forward Dividend Yield % too high?
Zydus Lifesciences' current Forward Dividend Yield % is 0.09%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.03. Zydus Lifesciences' value of 0.09% is 95.6% below this industry median. Based on the distribution chart, Zydus Lifesciences ranks #500 out of 510 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zydus Lifesciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zydus Lifesciences ranks #500 out of 510 companies for Forward Dividend Yield %. This places Zydus Lifesciences in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. Zydus Lifesciences' value of 0.09% is 95.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zydus Lifesciences's current Forward Dividend Yield % of 0.09% is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Zydus Lifesciences and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zydus Lifesciences's current Forward Dividend Yield % is 0.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,157.57, compared to a current price of ₹1,129.75 — trading 2.4% below its estimated fair value. The current Forward Dividend Yield % is 0.09% and 95.6% below the Drug Manufacturers industry median of 2.03. Zydus Lifesciences' overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current Forward Dividend Yield % is 0.09% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?
Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued.
The current stock price of ₹1,129.75 is trading 2.4% below its estimated GF Value™ of ₹1,157.57.
GuruFocus considers Zydus Lifesciences to be Fairly Valued.
Key valuation signals for BOM:532321:
Forward Dividend Yield %: 0.09%
GF Value™: ₹1,157.57 vs. price of ₹1,129.75 (2.4% below fair value)
Industry Position: 95.6% below the Drug Manufacturers median (#500 of 510)
No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
95GF Score
Get the complete analysis for BOM:532321
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532321 has been successfully added to your 
